We investigated the contribution of corticotropin-releasing factor (CRF) receptors types 1 and 2 (CRF 1 and CRF 2 ) in mediating the ACTH response to shock, alcohol injection, or endotoxemia in the rat. Peptidic (Astressin B and Astressin 2 -B) and nonpeptidic (NBI 30775) CRF antagonists were injected iv before the stressors at doses previously shown to be effective in blocking the corresponding receptors. Because NBI 30775, which specifically blocks CRF 1 , penetrates the brain following systemic injection, we also compared its effect with that of Astressin B, which primarily, though not exclusively, targets CRF 1 but does not cross the blood-brain barrier. Shocks, alcohol (4.5 g/kg, intragastrically) or lipopolysaccharide (LPS, 1 g/kg, iv) all significantly released ACTH. Astressin B or NBI 30775 markedly decreased the effect of shocks or alcohol and also interfered, though less significantly so, with the influence of LPS. In contrast, specific blockade of CRF 2 with Astressin 2 -B, although not significantly altering the overall ACTH response to shocks, alcohol, or LPS, slightly enhanced ACTH levels during the early phase of some of these responses. C ORTICOTROPIN-RELEASING FACTOR (CRF) is recognized as a central mediator of the body's ability to respond to stress. Initially isolated from ovine hypothalamus and characterized as a 41-amino acid peptide in 1981 (1), CRF was subsequently characterized from rat hypothalami (2) and the identical structure for human CRF was deduced on the basis of the cDNA sequence of the human CRF precursor gene (3). Presently, more than a dozen members of the CRF family (including sauvagine, urotensins, and urocortins) have been described. CRF plays a major role in the maintenance or restoration of homeostasis by stimulating the activity of the hypothalamic-pituitary-adrenal (HPA) axis (4). It also acts within the central nervous system to control immune (5), reproductive (6), gastrointestinal/ingestive (7, 8) , and cardiovascular (9) functions, as well as catecholamine release (10), drug withdrawal (11), behavior (12), and mood and anxiety (13). CRF also acts through the release of adrenal corticosteroids to alter immune parameters (1) and to participate in the regulation of carbohydrate metabolism by enhancing the availability of glucose (reviewed in Dallman et al., Ref. 14). Finally, the broad central and peripheral distribution of the peptide and its two classes of seven-transmembrane-helix G protein-coupled CRF receptors (15-21) support the notion that CRF is also an important local neurotransmitter within the central nervous and immune systems, among others.
C ORTICOTROPIN-RELEASING FACTOR (CRF) is rec-
ognized as a central mediator of the body's ability to respond to stress. Initially isolated from ovine hypothalamus and characterized as a 41-amino acid peptide in 1981 (1), CRF was subsequently characterized from rat hypothalami (2) and the identical structure for human CRF was deduced on the basis of the cDNA sequence of the human CRF precursor gene (3) . Presently, more than a dozen members of the CRF family (including sauvagine, urotensins, and urocortins) have been described. CRF plays a major role in the maintenance or restoration of homeostasis by stimulating the activity of the hypothalamic-pituitary-adrenal (HPA) axis (4) . It also acts within the central nervous system to control immune (5), reproductive (6) , gastrointestinal/ingestive (7, 8) , and cardiovascular (9) functions, as well as catecholamine release (10) , drug withdrawal (11) , behavior (12) , and mood and anxiety (13) . CRF also acts through the release of adrenal corticosteroids to alter immune parameters (1) and to participate in the regulation of carbohydrate metabolism by enhancing the availability of glucose (reviewed in Dallman et al., Ref. 14) . Finally, the broad central and peripheral distribution of the peptide and its two classes of seven-transmembrane-helix G protein-coupled CRF receptors (15) (16) (17) (18) (19) (20) (21) support the notion that CRF is also an important local neurotransmitter within the central nervous and immune systems, among others.
We and others have provided ample evidence that in rats, immunoneutralization of endogenous CRF significantly blunted the ACTH response to most known exteroceptive stressors (also called neurogenic), which involve a distinct cognitive and/or affective component comprised of footshocks and restraint (22, 23) , as well as to interoceptive (systemic) stressors, whose essential features are not consciously appreciated and which involve inflammatory and infectious insults (reviewed in Ref. 24 ). Understanding the mechanisms through which CRF influences the HPA axis, requires knowledge of the type of receptor(s) through which this peptide acts within this axis, and in particular how it stimulates ACTH release. Present consensus holds that type 1 CRF receptors (CRF 1 ), which are found on pituitary corticotrophs (see Ref. 25) , represent the primary receptors that mediate stress-induced increases in ACTH levels. This concept was first derived from the observation that mice lacking the CRF 1 receptor showed a significantly blunted ACTH response to restraint (26, 27) . On the other hand, mice lacking the CRF 2 gene tended to exhibit a slightly exaggerated stress-induced ACTH release, at least in the early phase of this response (27, 28) . Interestingly, however, restraint-induced ACTH secretion in mice lacking both receptors has been reported by some investigators (29) , though not others (27) , to be smaller than that of mice only lacking CRF 1 . Whether this is due to compensatory mechanisms due to the lack of both CRF receptor types, or to other causes, has not been determined. Another puzzling aspect of the role of CRF receptors in mediating ACTH release is our finding that CRF 1 Ϫ/Ϫ mice release very significant amounts of ACTH when exposed to interoceptive (i.e. immune) stressors (30) , which stands in stark contrast to their inability to respond to exteroceptive stimuli (see above). While the elevated levels of IL-6 measured in CRF 1 Ϫ/Ϫ mice injected with LPS or turpentine (30) have been invoked as potentially responsible for releasing ACTH in the absence of CRF drive (at least through the CRF 1 receptor), this issue has not been settled. On the other hand, the lack of CRF 1 leads to a significant loss of ACTH response to LPS in rats (31) , though this loss is of lesser magnitude than that observed following exposure to shocks or injection with alcohol (32) . In this species, it was determined that proinflammatory cytokines did not mediate the ACTH response to the immune stressors (31) .
The present work was carried out to investigate the specific role of CRF 1 and CRF 2 in mediating the rat HPA axis response to stressors. The experiments were performed in rats to examine the consequence of the specific blockade of CRF receptors in a model unencumbered by the possible influence of compensatory mechanisms present during embryonic development of genetically altered mice. We used two types of CRF antagonists, peptidic and nonpeptidic. Peptidic antagonists allowed us to specifically block pituitary CRF receptors without altering receptors within the brain, particularly in regions of the hypothalamus that participate in the ACTH response to stressors. The disadvantage of this approach is that, although we have a peptidic antagonist specific for CRF 2 (Astressin 2 -B, Ref. 33) , the antagonist used to block CRF 1 (Astressin B, Refs. 34 and 35) also provides some blockade of CRF 2 . We therefore also investigated the effect of a nonpeptidic antagonist which is specific for CRF 1 (see Ref. 36 , in which NBI 30775 is referred to as R121919). This reagent provided specific information regarding the role of CRF 1 , but because it penetrates the brain following its peripheral administration (36), it did not allow us to uncouple its influence on pituitary and hypothalamic CRF 1 . The two types of antagonists were tested in three models of stress: alcohol injection, exposure to inescapable footshocks and endotoxemia. We show here that, whereas pituitary CRF 1 receptors are the primary mediators of the rat ACTH responses, CRF 2 receptors also modulate HPA axis activity.
Materials and Methods

Animals and protocols
Adult male Sprague Dawley (Harlan Sprague Dawley, San Diego, CA) rats (200 -220 g) were kept under standard light (lights on 0630 -1830 h) and feeding (rat chow and water ad libitum) regimens. Aseptic insertion of an intragastric (ig) cannulae was done under isoflurane anesthesia 9 -10 d before the assay (37) . A right jugular iv catheter was inserted 2-3 d before testing (37) . All animals were singly housed to prevent chewing of the cannulae. In view of the limited blood volume that can be withdrawn from rats without hemorrhage-induced activation of the HPA axis, not all time-courses could be studied in the same groups of animals. Also, it must be noted that not all comparisons were carried out in the same assay because this would have resulted in experiments that were too complex. Thus, for example, depending on the number of rats required per experimental group, we sometimes compared the influence of Astressin B and Astressin 2 -B in one experiment, and that of NBI 30775 and Astressin B in another.
On the day of the experiment, the animals were moved to a soundproof room, singly housed in opaque buckets, and left undisturbed for 3 h. The antagonists or their vehicle were injected iv 15-20 min before CRF or the stressor. Blood samples (0.3 ml) were taken through the iv cannula in undisturbed rats and immediately replaced with an equivalent volume of apyrogenic isotonic saline. They were drawn into tubes that contained EDTA (10 l of a 60 mg/ml solution) and placed on ice. They were centrifuged at 4 C, and plasma was stored at Ϫ20 C until assayed.
All protocols were approved by The Salk Institute Institutional Animal Use and Care Committee.
Electrofootshocks
All animals were tested in the shockers, in which they were exposed to the shocks (shocked) or not (controls). Mild, inescapable footshocks (0.5 mA, 1 sec duration, 2 shocks/min) were delivered to the rats' paws using a Coulbourn HO2-08 grid floor shocker controlled by a Macintosh computer (Coulbourn Instruments, Allentown, PA) (38) . Because of the low voltage used, this procedure does not cause injury and is considered primarily an emotional stressor accompanied by a modest amount of physical discomfort.
Reagents
Rat/human (r/h) CRF and the peptidic CRF antagonists Astressin B (34) and Astressin 2 -B (33) were synthesized by solid phase methodology (33, 34) . A stock solution was made in apyrogenic water, and subsequent dilutions were made in 0.04 m PBS containing 0.1% crystalline BSA (to prevent nonspecific binding to glassware) and 0.01% ascorbic acid (to prevent oxidation). The nonpeptidic pyrrolopyrimidine CRF 1 antagonist NBI 30775 was synthesized as described in (36, 39) , solubilized in water containing 5% Cremophor (Sigma, St. Louis, MO), sonicated and mixed with 0.1 n NaOH for pH adjustment. Astressin B blocks CRF 1 and CRF 2 (34), Astressin 2 -B is specific for CRF 2 (33) and NBI 30775 specifically blocks CRF 1 (36) . These antagonists were injected iv 20 -30 min before the stressors at doses (Astressin B and Astressin 2 -B, 30 g/kg; NBI 30775, 4 -6 mg/kg) and over a time frame previously shown to fully block ACTH release (33) (34) (35) (36) . Alcohol was diluted with saline so that its final injected concentration was 18% (vol/vol). It was injected through the indwelling ig cannulae to otherwise undisturbed, unhandled rats. The dose chosen (4.5 g/kg, ig) induces a moderate degree of intoxication and significant as well as reliable increases in plasma ACTH levels (37) . LPS from Escherichia coli (serotype 026:B6) was purchased from Sigma and diluted in apyrogenic saline. It was injected iv at a dose (1 g/kg) that is comparatively much lower than that usually reported in the literature, and was designed to significantly release ACTH without inducing severe sickness or disrupting the blood-brain barrier (BBB; Ref. 40) .
ACTH assay
Plasma ACTH levels were determined by a commercially available two-site immunoradiometric assay (Allegro kit, Nichols Institute, San Juan Capistrano, CA), which has been validated for the measurement of rat ACTH (41) . Assay sensitivity was 5 pg/ml, and the intraassay and interassay coefficients of variation were 3.2 and 6.8%, respectively.
Cytokine assays
TNF-␣ and IL-6 levels were measured by ELISA (TNF-␣: R&D Systems, Minneapolis, MN; IL-6: Endogen, Inc., Rockford, IL) that were validated in our laboratory by comparing standard curves with serial plasma dilutions (42) .
Statistical analysis
Statistical analyses were performed by one-or two-way ANOVA for the factors of group and time. The least square means post hoc tests were used to make comparisons between groups at a particular time point, and between time points within a particular group. Differences were considered statistically significant at P Ͻ 0.05.
Results
Comparison between the effect of Astressin B, Astressin 2 -B, or NBI 30775 on the ACTH response to r/hCRF (Fig. 1)
These experiments were designed to compare the effect of the blockade of CRF receptors on the ACTH response to exogenous CRF (2 g/kg, iv), and to ensure that CRF 1 antagonists completely abolished this response. Astressin B (30 g/kg) or NBI 30775 (6 mg/kg) virtually abolished CRFinduced ACTH release (Fig. 1) . In contrast, Astressin 2 -B slightly reduced this response (similar results were observed in two out of three experiments).
Comparison between the effect of Astressin B or Astressin 2 -B on the ACTH response to shocks, LPS or alcohol (Figs. 2-4)
Astressin B. These experiments were designed to compare the effect of Astressin B and Astressin 2 -B in modulating the ACTH response to shocks, LPS, alcohol, or their vehicle. As these peptidic antagonists do not cross the BBB, these results provided information regarding the specific role of pituitary CRF receptors, which could not be addressed with the nonpeptidic CRF 1 antagonist NBI 30775. There were no significant (P Ͼ 0.05) differences between ACTH release of animals injected with the vehicle or the antagonists alone (Figs. 2-4) . All stressors induced the expected rise in ACTH concentrations, and in all three cases these responses were significantly (P Ͻ 0.01) reduced by Astressin B (30 g/kg; Figs. 2-4A ). It should be noted, however, that the magnitude of the decrease in the ACTH response to LPS was not as large as that seen in the shocks or alcohol model, a phenomenon that we have previously attributed to the role of vasopressin (VP) in the latter phase of ACTH release during endotoxemia (43) .
Astressin 2 -B. When we examined ACTH responses over the time courses that we have used in the past for the shocks (illustrated in A panels of Figs. 2-4) , LPS, and alcohol models, Astressin 2 -B (30 g/kg) only significantly (P Ͻ 0.01) augmented ACTH release due to LPS (Fig. 4A ), but not shocks ( Fig. 2A) or alcohol (Fig. 3A) . In view of the reported early increase in ACTH release observed in CRF 2 Ϫ/Ϫ mice exposed to restraint stress (27, 28) , we thought that it would also be important to examine earlier parts of ACTH responses in our models (illustrated in B panels of Figs. 2-4) . We therefore measured ACTH levels shortly after exposure to shocks or injection with LPS or alcohol, in rats injected with this antagonist. In these experiments, Astressin 2 -B indeed significantly (P Ͻ 0.01) enhanced the early ACTH response to shocks (Fig. 2B) or LPS (Fig. 4B) , but not to alcohol (Fig. 3B) . 
Consequence of specifically blocking CRF 1 and CRF 2 , separately or together, on the ACTH response to shocks, LPS or alcohol (Figs. 5-7)
The experiments described above sought to give information regarding blockade of pituitary, but not hypothalamic, CRF receptors on ACTH responses to stressors and were therefore conducted with peptidic antagonists that do not cross the BBB. However, it must be noted that Astressin B, which was used to block CRF 1 , also targets CRF 2 . Consequently, these studies did not allow us to specifically and separately address the role of each receptor type. The experiments described below address this point, though the ability of NBI 30775 to cross the BBB (36) means that we now cannot distinguish between the role of pituitary and hypothalamic CRF 1 . Nevertheless, they provided a comparison with results previously published in mutant mice lacking the gene for both receptors.
The rats displayed the expected ACTH response to shocks, LPS, or alcohol, and blockade of CRF 1 by NBI 30775 (6 mg/ kg) consistently decreased this response (Figs. 5-7) . Astressin 2 -B (30 g/kg) did not significantly alter the stimulatory effect of LPS or alcohol, but slightly augmented that of shocks (for an explanation of the discrepancy between these results and those illustrated in Fig. 4B , see Discussion). Combined blockade of CRF 1 and CRF 2 tended to lower plasma ACTH levels below those observed for treatment with NBI 30775 alone, though this difference did not usually reach statistical significance. (Fig. 8) We previously reported that removal of endogenous CRF significantly enhanced the IL-6 response to LPS (31) , and that mice lacking the CRF 1 gene exhibited an elevated IL-6 response to endotoxemia (30) . The present experiments were designed to extend these studies to TNF-␣, and investigate the role of CRF 1 and CRF 2 on TNF-␣ and IL-6 release in rats injected with LPS. LPS induced the expected rise in plasma TNF-␣ and IL-6 levels (Fig. 8) . Both responses were significantly (P Ͻ 0.05-0.01) augmented by either NBI 30775 (6 mg/kg) or Astressin 2 -B (30 g/kg), and blockade of both receptor types did not provide a further increase.
Consequence of specifically blocking CRF 1 or CRF 2 on the TNF-␣ and IL-6 response to LPS
Discussion
Using mice lacking the gene for specific CRF receptors as well as the injection of peptidic and nonpeptidic CRF antagonists to rats, a number of laboratories have suggested the critical importance of pituitary CRF 1 receptors in mediating the HPA axis responses to exteroceptive stressors such as shocks and restraint (26, 27, 29, 32, 35, 44, 45) . We confirmed and extended these results here by showing that both the peptidic Astressin B and the nonpeptidic antagonist NBI 30775 significantly blunted the ability of shocks, alcohol, or endotoxemia to release ACTH. As these antagonists targeted different compartments of the HPA axis (i.e. Astressin B only blocked pituitary CRF 1 and CRF 2 , whereas NBI 30775 blocked pituitary and hypothalamic CRF 1 ), our results could not uncover any differences between the importance of peripheral and central CRF 1 . It must be also noted that blockade of CRF 1 receptors only partially reduced LPS-induced ACTH release, which stands in contrast to the higher effectiveness of Astressin B or NBI 30775 in the shock or alcohol paradigms. We had previously reported that, although mice lacking the CRF 1 gene showed a significantly decreased ACTH response to restraint compared with wild-type animals (26, 27) , their ACTH response to immune stimuli was only minimally impaired (30) . Here we report that acute blockade of CRF 1 in the rat, which does not involve some of the compensatory mechanisms present when the corresponding gene is absent during embryonic development, is not as detrimental to pituitary activity during endotoxemia as it is during exposure to shocks. The markedly enhanced IL-6 release measured in CRF 1 Ϫ/Ϫ mice injected with turpentine or LPS (30) , coupled to the fact that mice lacking IL-6 show a decreased ACTH response to immune stressors (40) , had suggested that in mice, cytokines might stimulate ACTH release independently of CRF. The situation appears different in rats because we showed that endogenous CRF immunoneutralization significantly decreased ACTH levels and increased IL-6 concentrations following LPS injection (31) , an observation that is supported by the present work. Furthermore, exposing isolated rat pituitary cells to LPS for 6 h increased IL-6 concentrations in the medium but did not alter ACTH release (46) . Collectively, these results argue against a critically important influence of these proinflammatory cytokines on ACTH release in rats, which is not mediated by CRF. Nevertheless, as we show here, CRF 1 receptors are not as important for the rat ACTH response to LPS as they are upon exposure to shocks or alcohol. Whereas VP participates in this response (47, 48) , its ability to release ACTH depends on the presence of endogenous CRF and will be decreased by blocking interactions with this peptide (49) . Indeed, both shocks and alcohol stimulate ACTH secretion through mechanisms that also depend on VP (50, 51) , but as we show here, their influence was significantly decreased by NBI 30775. As prostaglandins play a critical role in LPS-induced ACTH release (48) but do not interact with the stimulatory effect of CRF on the corticotrophs (52), the relative lack of effectiveness of NBI 30775 in the endotoxemic rat may be, at least in part, due to the contribution of eicosanoids at a suprapituitary level. Finally, we need to address the questions of whether the use of peptidic and nonpeptidic CRF antagonists allowed us to dissociate the influence of peripheral and central CRF receptors in regulating HPA axis activity. By comparing the influence of the systemic injection of peptidic CRF antagonists that do not cross the BBB with that of intracerebroventricular injection, we had proposed that, whereas pituitary CRF 1 receptors were critical for the rat ACTH response to shocks and alcohol injection, hypothalamic CRF 1 did not play a significant role (53) . The similarity between the effect of Astressin B and NBI 30775, which we report here, provides further support for this hypothesis.
The role of CRF 2 in mediating ACTH release was first demonstrated by studies conducted in CRF 2 Ϫ/Ϫ mice. Originally, the finding that these receptors were not present in corticotrophs (25, 54) had suggested that they were probably not essential for the ability of stressors to release ACTH. This concept has been somewhat challenged by the fact that mice lacking the CRF 2 gene displayed slightly enhanced ACTH levels during parts of initial phase of this response and/or an early termination of ACTH secretion (27, 28, 55) . In the present work, we provide data supporting the hypothesis that in the rat, blockade of CRF 2 alone may also, at least in some experiments, result in a slight enhancement of the early ACTH response to shocks, alcohol, and LPS. The question of where CRF 2 receptors act within the HPA to alter the ACTH response to stressors has been investigated in a number of studies. Some investigators have identified CRF 2 ␣ receptors in the rat PVN (56, 57), but levels of these transcripts are very low, if detectable at all, and are not up-regulated by stressors (57-62). CRF 2 ␣ receptors are also found in limbic regions (54, 60 ) that tonically restrain PVN activity through GABAdependent mechanisms (63). Their absence in mutant mice might therefore result in disinhibited PVN neuronal activity, and hence increased ACTH release. However, in our rat models, blockade of PVN and/or limbic CRF 2 by the peripheral injection of Astressin 2 -B is highly unlikely because this peptidic antagonist is not expected to cross the BBB. We therefore examined the ability of Astressin 2 -B to alter CRFinduced ACTH release and surprisingly, found that in two out of three experiments, the response was slightly decreased. Whether this phenomenon plays a role in the decreased ACTH response of rats injected with both NBI 30775 and Astressin 2 -B, remains to be determined. At present, there does not seem to be much experimental ground to provide the basis for fruitful explanations for these somewhat conflicting observations. One possibility is that pre-and/or perinatal events, over which investigators have no control when they use commercially purchased rodents, may influence later HPA axis responses, and in particular the role of specific CRF receptors. There is of course much information regarding the influence of prenatal stress, maternal separation or handling shortly after birth, on the adult offspring CRF and ACTH release (see, for example, Refs. 64 -67). Whether any of these manipulations are capable of altering the role played by pituitary CRF 2 in selected batches of rats, remains to be determined, but it might be wise to keep in mind that conditions outside our control may influence results in a seemingly unpredictable fashion.
A last comment pertains to the role of endogenous CRF in regulating the production of proinflammatory cytokines. We showed here that pretreatment with Astressin B, NBI 30775 or Astressin 2 -B augmented LPS-induced TNF-␣ and IL-6 release. Depending on the experimental model, peripheral CRF has been reported to augment or inhibit immune responses independently of glucocorticoids (68 -72). For example, we found that the peripheral injection of CRF antibodies significantly decreased symptoms in arthritic rats (73). These results, which were recently confirmed with the use of a nonpeptidic CRF antagonist in arthritic Lewis rats (74), suggest a proinflammatory role of this peptide. However, we also observed that immunoneutralization of endogenous CRF augmented the TNF-␣ and IL-6 response to LPS (31), which supports the hypothesis that, in the rat, CRF acts peripherally to inhibit the release of these particular cytokines. The present data confirm and extend these latter findings, and further indicate that the influence of the peptide is likely exerted through both subtypes of CRF receptors (type 1 and 2). The observation that blockade of both receptor types did not augment cytokine levels above those measured in the presence of NBI 30775 or Astressin 2 -B alone further suggests that the contribution of these receptors is not additive. Interestingly, a recent report indicated that in mice, blockade of CRF 1 suppressed LPS-induced TNF-␣ and IL-6 release (75). We therefore need to consider the possibility that the role of CRF on the immune system might be species specific.
In summary, our results confirm that pituitary CRF 1 receptors are essential for the rat ACTH response to extero-as well as interoceptive stressors, even though they appear to be more critical in mediating the ACTH-releasing effectiveness of shocks and alcohol, compared with LPS. This observation may indicate a species difference in the role of these receptors because, in mice, the absence of CRF 1 only marginally compromises the ACTH response to LPS (30) . We also extended earlier results obtained in mutant mice and showed that CRF 2 in areas not protected by the BBB also play a role in regulating corticotroph function. Finally, we showed that blockade of CRF 1 and CRF 2 enhances TNF-␣ and IL-6 release following LPS injection. This observation not only supports the hypothesis that peripheral endogenous CRF restrains the production of these cytokines, but also that TNF-␣ and IL-6 do not provide a significant drive to ACTH release in the absence of CRF. Collectively, these data extend our previous understanding of the role played by CRF receptors in regulating HPA axis activity in the rat.
